News

In an informative new blog post - AMSBIO reflects on a selection of the groundbreaking life science and biomedical research undertaken by its customers during 2023. From deciphering the intricacies of cancer progression mechanisms to revolutionising wound care, AMSBIO is delighted to have played a supporting role in these scientific endeavours.

MHA is excited to announce the appointment of Chris Liu as Partner who will lead our successful Transfer Pricing Team in the International Marketplace.

Biocair, a global leader in GDP logistics for the pharmaceutical, biotechnology and life sciences sectors, is proud to announce its partnership with Aramex Ireland to expand its presence in the Irish market.


With Biocair's focus on providing the most comprehensive time-sensitive and temperature-controlled logistics services available, and Aramex Ireland’s operations and facilities to deliver life science goods, the partnership is poised to grow an established presence in Ireland for the life science market.

The companies are working together on next-generation technology in the fast-growing field of synthetic biology. This new technology will improve the quality, speed, and cost of developing synthetic biological solutions such as life-saving vaccines, medicines, treatments, and therapies.

BugBiome wins a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures

BioMavericks awarded the wildcard prize as voted for by the audience at the GIANT Health Healthcare Investment Show on 5th December

ValiRx Plc, a life science company focusing on cancer therapeutics and women's health, has announced that ValiRx subsidiary, ValiSeek Ltd, has entered into an exclusive option agreement to license VAL401 with Ambrose Healthcare Ltd, a private UK specialist pharmaceutical company.


Ambrose Healthcare is seeking to develop new treatments for rare diseases and patients managed in hospitals and specialist care. The company, incorporated in 2022, has an internationally experienced leadership team with deep knowledge of the pharmaceutical industry.

CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing



  • PhysioMimix NASH assay used to provide human-relevant data on compound efficacy for Inipharm’s lead candidate, INI-822

  • Submission represents first example of an OOC provider’s data supporting clinical progression of a drug for metabolic, fibrotic liver disease


 

Sandwich, Kent, UK, 4th December 2023 / Sciad Newswire / Discovery Park Ventures (DPV) announces the expansion of its early-stage life science fund from £1m to £3m, in order to capitalise on exciting investment opportunities and support its existing portfolio. The fund’s investors have committed an additional £2m, which will also enable the fund to take larger stakes in companies that strongly align with its strategic objectives.

Arecor Therapeutics plc

(“Arecor” or the “Group”)


ARECOR SIGNS CO-DEVELOPMENT AND EXCLUSIVE LICENCE OPTION AGREEMENT WITH LEADING GLOBAL MEDICAL PRODUCTS COMPANY FOR IN-HOUSE SPECIALITY HOSPITAL PRODUCT


Arecor-developed, Arestat™-enabled product is potentially first ready-to-dilute liquid formulation of a high-value oncology therapy

Seasoned Life Sciences pharmaceutical physician and leader joins the region’s Life Science & Healthcare membership organisation

 

Pages